Portfolio holdings

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Woodford Patient Capital Trust plc

Home > Funds > Woodford Patient Capital Trust plc > Portfolio Holdings

We recognise that openness and transparency are key in building client understanding and we ensure that our clients get unprecedented levels of clear and relevant information about their investments, including unparalleled access to our Investment team and transparency into our portfolio construction.

To keep our investors informed, we are committed to providing full disclosure of the Woodford Patient Capital Trust’s holdings on a monthly basis.

Please find the portfolio holdings as at 31 August 2017 below.

The details set out are for information purposes only. Care is taken in ensuring this is accurate as at the stated date. However, this is not guaranteed and the portfolio may change at any time. This does not constitute investment advice or any recommendation with regard to the listed stocks.

Register now to receive Portfolio disclosure alerts by email.

Woodford Patient Capital Trust plc As at 31 August 2017
  Name Industry % (weight)
1 Prothena Health Care 16.20
2 Purplebricks Financials 11.80
3 Oxford Nanopore (unquoted) Health Care 8.47
4 Immunocore A (unquoted) Health Care 7.21
5 Theravance Biopharma Health Care 4.24
6 Proton Partners International (unquoted) Health Care 4.05
7 Mereo Biopharma Health Care 3.92
8 Oxford Sciences Innovation (unquoted) Financials 3.24
9 Atom Bank (unquoted) Financials 2.77
10 Gigaclear (unquoted) Telecommunications 2.64
11 Idex Technology 2.49
12 Autolus (unquoted) Health Care 2.47
13 Kymab B Pref  (unquoted) Health Care 2.44
14 Arix Bioscience  Financials 2.13
15 Malin Financials 2.11
16 Ultrahaptics Pref (unquoted) Technology 1.82
17 Ombu Pref (unquoted) Financials 1.63
18 4D Pharma Health Care 1.56
19 Thin Film Electronics Industrials 1.29
20 A J Bell (unquoted) Financials 1.21
21 Xeros Industrials 1.19
22 Inivata (unquoted) Health Care 1.17
23 SciFluor Life Sciences (unquoted) Health Care 1.03
24 Cell Medica (unquoted) Health Care 1.03
25 ReNeuron Health Care 1.00
26 Touchstone Innovations Financials 0.98
27 Allied Minds Financials 0.98
28 Cequr (unquoted) Health Care 0.96
29 Precision Biopsy (unquoted) Health Care 0.91
30 AMO Pharma (unquoted) Health Care 0.91
31 Evofem D (unquoted) Health Care 0.89
32 Draper Esprit Financials 0.87
33 Silence Therapeutics Health Care 0.87
34 Industrial Heat (unquoted) Industrials 0.86
35 Drayson Technologies (unquoted) Technology 0.81
36 Seedrs (unquoted) Financials 0.80
37 Vernalis Health Care 0.80
38 Mission Therapeutics (unquoted) Health Care 0.73
39 Benevolent AI (unquoted) Technology 0.68
40 Metalysis (unquoted) Industrials 0.64
41 Nexeon (unquoted) Industrials 0.62
42 Benchmark Health Care 0.59
43 Mercia Technologies Financials 0.57
44 Mafic (unquoted) Industrials 0.55
45 Netscientific Health Care 0.54
46 Kind Consumer C (unquoted) Consumer Goods 0.53
47 Federated Wireless (unquoted) Technology 0.50
48 Industrial Heat A2 Pref (unquoted) Industrials 0.49
49 Ratesetter (unquoted) Financials 0.47
50 Tissue Regenix Health Care 0.44
51 Accelerated Digital Ventures A (unquoted) Financials 0.40
52 Abzena Health Care 0.37
53 Ultrahaptics (unquoted) Technology 0.36
54 PsiOxus (unquoted) Health Care 0.36
55 RM2 International (Convertible Pref)   Industrials 0.36
56 Dementia Discovery Fund (unquoted) Health Care 0.31
57 Novabiotics (unquoted) Health Care 0.29
58 Horizon Discovery Health Care 0.28
59 Oxford Pharmascience Health Care 0.27
60 Itaconix Basic Materials 0.26
61 Kind Consumer (unquoted) Consumer Goods 0.25
62 Cambridge Innovation Capital (unquoted) Financials 0.23
63 Fibre 7 (unquoted) Industrials 0.20
64 Verseon Health Care 0.20
65 Econic (unquoted) Industrials 0.19
66 American Financial Exchange (unquoted) Financials 0.18
67 RM2 International Industrials 0.17
68 Drayson Technologies C (unquoted) Technology 0.14
69 Origin (unquoted) Health Care 0.10
70 Northwest Biotherapeutics Health Care 0.09
71 Origin (convertible pref) (unquoted) Health Care 0.09
72 Evofem C (unquoted) Health Care 0.08
73 Halosource Reg S Industrials 0.06
74 Kind Consumer B (unquoted) Consumer Goods 0.04
75 Industrial Heat A3 (unquoted) Industrials 0.04
76 Midatech Pharma Health Care 0.02
77 Sphere Medical Health Care 0.02
78 Ombu (unquoted) Financials 0.01

What are the risks?

  • Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy
  • Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses
  • As it can take years for young businesses to fulfil their potential, this investment requires patience
  • The value of the trust as well as any income it pays will fluctuate which may partly be the result of exchange rate changes
  • The price of shares in the trust is determined by market supply and demand, and this may be different to the net asset value of the trust
  • The trust may invest in overseas securities and be exposed to currencies other than pound sterling
  • The trust may invest in unquoted securities, which may be less liquid and more difficult to realise than publicly traded securities

Important information

We do not give investment advice so you need to decide if an investment is suitable for you. If you are unsure whether to invest, you should contact a financial adviser. The trust currently intends to conduct its affairs so that its securities can be recommended by IFAs to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address 40 Dukes Place, London EC3A 7NH.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: info@oligofunds.ch. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

© 2017 Woodford Investment Management Ltd.
All rights reserved.

By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement